High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency Article

Ballester, OF, Tummala, R, Janssen, WE et al. (1997). High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency . 20(8), 653-656. 10.1038/sj.bmt.1700950

cited authors

  • Ballester, OF; Tummala, R; Janssen, WE; Fields, KK; Hiemenz, JW; Goldstein, SC; Perkins, JB; Sullivan, DM; Rosen, R; Sackstein, R; Zorsky, P; Saez, R; Elfenbein, GJ

fiu authors

abstract

  • Six patients with multiple myeloma and chronic renal insufficiency (serum creatinine > 3.0 mg/dl), including four on dialysis, received high-dose busulfan and cyclo-phosphamide (BUCY) followed by autologous peripheral stem cell transplantation. Peripheral blood stem cells were collected after priming with cyclophosphamide, etoposide and G-CSF. Patterns of engraftment and toxicities were not apparently different from those seen in myeloma patients with normal renal function. There was one toxicity-related death, resulting from a massive spontaneous subdural hematoma. One patient died of disease progression 6 months after transplant, while the remaining four patients are alive and free of myeloma progression 6 to 39 months after high-dose therapy. Two of these patients have remained in complete remission for 28 and 39 months. Our experience suggests that high-dose therapy with BUCY and autologous peripheral blood stem cell rescue is feasible in patients with multiple myeloma and renal failure.

publication date

  • October 2, 1997

Digital Object Identifier (DOI)

start page

  • 653

end page

  • 656

volume

  • 20

issue

  • 8